9 completed, 4 unknown, 3 recruiting, 2 active not recruiting. 6 Phase 3, 4 Not applicable, 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
Follow Administration, Oral: new trials by email Literature Review of Administration, Oral trials Research Report on Administration, Oral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration - Achondroplasia | Phase 2 | Recruiting | QED Therapeutics, a BridgeBio company | 77 | 2025-11-19 | 2026-07-13 |
| Acute Effect of Polyphenols Supplementation on Endothelial Function and Exercise Related Markers, in Physically Active Healthy Volunteers. Oral administration - Vasodilation, Exercise | Not applicable | Active not recruiting | Nexira | 38 | 2025-09-01 | 2026-04-13 |
| Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions Oral administration - Microecological Therapy, Probiotic Intervention | Early Phase 1 | Active not recruiting | Zhujiang Hospital | 30 | 2024-12-05 | 2026-01-07 |
| Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants HRS-5041 dose level 1, HRS-5041 dose level 2 - Prostate Cancer | Phase 1 | Completed | Atridia Pty Ltd. | 24 | 2024-09-25 | 2025-03-18 |
| Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma Temozolomide（TMZ） injection or oral administration, Albumin-Bound Paclitaxel(ABX) intravenous drip, Specific mode electroacupuncture stimulation(SMES) intervention - Glioma | Phase 3 | Recruiting | The Third Affiliated hospital of Zhejiang Chinese Medical University | 58 | 2024-04-01 | 2024-03-26 |
| Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT). - Acute Myeloid Leukemia | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 54 | 2024-01-01 | 2024-01-31 |
| A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration - Asthma | Phase 1 | Completed | AstraZeneca | 110 | 2022-07-08 | 2023-03-20 |
| Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis Intrauterine infusion, Oral administration - Chronic Endometritis | Phase 2 | Unknown | Genesis Athens Clinic | 90 | 2021-01-19 | 2023-02-24 |
| Daily Vitamin D for Sickle-cell Respiratory Complications Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU, Placebo oral tablet - Sickle Cell Disease, Anemia, Sickle Cell | Phase 2 | Completed | Columbia University | 58 | 2020-09-15 | 2025-09-24 |
| The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat "Yohimbine", "Hydrocortisone", "Yohimbine + Hydrocortisone" - Yohimbine, Hydrocortisone | Not applicable | Completed | Charite University, Berlin, Germany | 167 | 2019-11-01 | 2022-03-15 |
| G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea 2.0g G-PUR®, oral administration, Placebo, oral administration - Irritable Bowel Syndrome With Diarrhea (IBS-D) | Not applicable | Unknown | Glock Health, Science and Research GmbH | 30 | 2019-10-02 | 2020-11-13 |
| Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients TG02 capsules oral administration, BIW in every 28d - High-grade Gliomas | Phase 1 | Unknown | Lee's Pharmaceutical Limited | 15 | 2019-03-22 | 2020-04-14 |
| ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose) - Alopecia | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 87 | 2018-06-11 | 2020-09-16 |
| The Comparison of Different Administration Routes of Pediatric Premedication Oral administration, Intramuscular injection, Rectal perfusion - Anesthesia | Phase 4 | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 80 | 2014-12-01 | 2014-12-10 |
| Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder Placebo, Vilazodone - Generalized Anxiety Disorder | Phase 3 | Completed | Forest Laboratories | 415 | 2013-04-30 | 2019-12-18 |
| Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder Placebo, Vilazadone - Generalized Anxiety Disorder | Phase 3 | Completed | Forest Laboratories | 402 | 2013-01-31 | 2019-12-18 |
| Clinical Study of Caffeine for Apnea of Prematurity NPC-11 for intravenous or oral administration. - Apnea of Prematurity | Phase 3 | Completed | Nobelpharma | 24 | 2011-08-01 | 2013-10-30 |
| Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas NPC-07 for oral administration - Malignant Glioma | Phase 3 | Completed | Nobelpharma | 45 | 2010-08-01 | 2012-04-27 |
| An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease Dimebon tablet for oral administration - Alzheimer's Disease | Phase 3 | Terminated | Pfizer | 5 | 2010-04-01 | 2012-10-02 |
Asthma (2) · Generalized Anxiety Disorder (2) · Glioma (2) · Achondroplasia (1) · Acute Chest Syndrome (1) · Alopecia (1) · Alzheimer Disease (1) · Anemia, Hemolytic, Congenital (1) · Anemia, Sickle Cell (1) · Aneurysm (1) · Apnea (1) · Avitaminosis (1) · Bone Diseases (1) · Central Nervous System Diseases (1) · Cognitive Dysfunction (1)
Forest Laboratories (2) · Nobelpharma (2) · Aclaris Therapeutics, Inc. (1) · AstraZeneca (1) · Atridia Pty Ltd. (1) · Charite University, Berlin, Germany (1) · Columbia University (1) · Genesis Athens Clinic (1) · Glock Health, Science and Research GmbH (1) · Lee's Pharmaceutical Limited (1) · Nexira (1) · Pfizer (1) · QED Therapeutics, a BridgeBio company (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (6) · China (4) · Australia (2) · Japan (2) · United Kingdom (2) · Austria (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Norway (1) · Singapore (1) · Spain (1)
Giovanna Forero, MA (2) · Dave Singh (1) · Dr Pablo Forte Soto (1) · Gary M Brittenham, MD (1) · Jorg Taubel (1) · Konstantinos Sfakianoudis, MD (1) · Margaret T Lee, MD (1) · Michael Wolzt, Prof. Dr. (1) · Rajkumar Chetty, Dr (1) · Soichiro Shibui, MD, PhD (1) · Susan Moran, RN (1) · Susumu Itoh, MD, PhD (1)
PMID 27486544, PMID 10761648, PMID 11180089, PMID 18676355, PMID 19269895, PMID 20685221, PMID 21676290, PMID 22460905, PMID 25669487, PMID 26291335, PMID 27188790, PMID 27232052, PMID 27407096, PMID 27742444, PMID 28434963, PMID 30654536, PMID 30733593, PMID 32142739, PMID 32335153, PMID 32506369, PMID 32599393, PMID 32832670, PMID 33122995, PMID 33649582, PMID 35552677, PMID 37142373, PMID 38581746, PMID 38902928, PMID 7636549